**Publication list – Diederik De Cock**

- **Articles in internationally reviewed academic journals**

1. **As First Author (accepted)**


This paper was elected for Research Highlight in *Nature Review Rheumatology*: 

Furthermore, this paper received some exposure in local newspapers and international sites:


2. **As Co-Author (accepted)**

Davies, R., Southwood, T., Kearsley-Fleet, L., et al. Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Archives of Disease in Childhood.


- **Articles in other academic journals**

- **Meeting abstracts, presented at (international) scientific conferences and symposia as 1st author**
  - De Cock, D., Verschueren, P., Corluy, L., et al. Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the CareRA trial Oral Presentation, Belgian Congress Rheumatology, Genk, September 2015.

De Cock, D., Verschueren, P., Corluy, L., et al. Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the CareRA trial Oral presentation. EULAR 2015, Rome, June 2015.


De Cock, D., Verschueren, P., Corluy, L., et al. Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDS for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CareRA trial Oral Presentation, Belgian Congress Rheumatology, Brussels, September 2014.


De Cock D and Verschueren P share a first co-authorship

Verschueren, P., De Cock, D., Corluy, L. et al. Associated with a glucocorticoid bridging scheme, Methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CareRA trial. EULAR 2014, Paris, June 2014.

De Cock D and Verschueren P share a first co-authorship

De Cock, D., Meyfroidt, S., Joly, J., Van der Elst, K., Westhovens R., Verschueren, P. on behalf of the CareRA study group. For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA. LATE BREAKING ABSTRACT. ACR 2013. San Diego, November 2013.


